National project : OPTIMA

Optimizing patient centered-care: a pragmatic randomized control trial comparing models of care in the management of prescription opioid misuse

OPTIMA Trial – QMN

Current status: RECRUITING

For more information:

514-291-3473 or 514-890-8000 ext. 30932

Amel Zertal, MSc
Clinical Research Coordinator
amel.zertal.chum@ssss.gouv.qc.ca

Eligibility Criteria:

  • Persons who have a substance use disorder and who use prescription opioid medication;
  • Be aged between 18 and 64 years of age inclusively;
  • Not on opioid agonist therapy at the moment (methadone or buprenorphine/naloxone);
  • Interested
  • in beginning a treatment.

Prevention and treatment of opioid use disorder (OUD) has become an urgent public health priority in Canada. To develop novel and more efficient treatment programs based on the real needs of individuals afflicted by prescription OUD, a strong foundation of evidence-based data is necessary and can only be built via large-scale multisite interventional studies such as OPTIMA.

Currently, opioid substitution is a widely used approach to treat patients addicted to prescription opioids. In Canada, methadone has long been the main standard of care treatment for opioid use disorder. The use of this synthetic opioid is heavily regulated given the risk of overdose and diversion toward the illicit market.

Recently, buprenorphine/naloxone has become a common alternative treatment appreciated by both clinicians and patients. However, while buprenorphine/naloxone has a better tolerability and safety profile than methadone, the model of care that was put in place for its use has been designed based on the strict methadone model. Therefore, there is a clear need for evaluating more adapted models of care that could facilitate buprenorphine/naloxone use in treatment settings.

Hence, the OPTIMA study will evaluate and compare these two different models of care for methadone and buprenorphine/naloxone, so to inform the Canadian clinical practice about the optimal use of these approaches.

The OPTIMA team

OPTIMA is a unique multicenter Canada-wide trial evaluating a new addiction care model that will potentially increase the appeal, adherence, and effectiveness of these treatments. The 4 CRISM-NPIs and their teams are working together with the overarching objective of comparing different models of care involving both Canadian standard of care treatments in opioid addiction, namely methadone and buprenorphine/naloxone (also known as Suboxone).

Nominated principal investigators

  • Cameron Wild, PhD
    Cameron Wild, PhD Prairies NPI
  • Evan Wood, MD, PhD
    Evan Wood, MD, PhD British Columbia NPI
  • Julie Bruneau, MD, MSc
    Julie Bruneau, MD, MSc Quebec-Atlantic NPI
  • Jurgen Rehm, PhD
    Jurgen Rehm, PhD Ontario NPI

OPTIMA regional principal investigators

  • Bernard Le Foll, MD, PhD
    Bernard Le Foll, MD, PhD Ontario Node
  • Didier Jutras-Aswad, MD, MSc
    Didier Jutras-Aswad, MD, MSc Quebec-Atlantic Node
  • Eugenia Socias, MD
    Eugenia Socias, MD British Columbia Node
  • Ronald Lim, MD
    Ronald Lim, MD Prairies Node

OPTIMA National Team

  • Aïssata Sako
    Aïssata Sako Research program manager
  • Didier Jutras-Aswad, MD, MSc
    Didier Jutras-Aswad, MD, MSc Lead RPI
  • Jill Fikowski, MPH
    Jill Fikowski, MPH National Research Coordinator

Clinical research coordinators

  • Amel Zertal, MSc
    Amel Zertal, MSc Clinical Research Coordinator - Quebec-Atlantic Node
  • Denise Adams, PhD
    Denise Adams, PhD Clinical Research Coordinator - Prairies Node
  • Jose Trigo, PhD
    Jose Trigo, PhD Clinical Research Coordinator - Ontario Node
  • Katrina Blommaert, MPH
    Katrina Blommaert, MPH Clinical research coordinator - BC node

Recruitment material

Start typing and press Enter to search